Nasdaq

Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome

SAN DIEGO, Feb. 24, 2022 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...
Seeking Alpha

Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD

Regulus Therapeutics Inc. achieved positive results in cohort 2 of phase 1b study, using RGLS8429 for patients with autosomal polycystic kidney disease; Improvement of PC1 & PC2 proteins and reduction ...
Nasdaq

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with ...

SAN DIEGO, Jan. 2, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the ...
Astronomy

The Sky Today on Thursday, October 16: The Moon rises with Regulus

The article details the celestial configuration of the waning Moon and Regulus in the constellation Leo for observation on October 15. Regulus is identified as a magnitude 1.4, quadruple-star system, ...
FierceBiotech

Regulus Expands Development of RG-101 through Clinical Trial Collaboration with GSK

LA JOLLA, Calif., Nov. 3, 2015 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs ...